Centeon Kankakee, Ill. plant resumes production pursuant to consent decree with FDA.
Executive Summary
CENTEON TO RESUME PRODUCTION AT KANKAKEE, IL. PLANT UNDER CONSENT DECREE between FDA and the blood products company; the consent decree will be filed the week of Jan. 27. The Rhone-Poulenc Rorer and Hoechst joint venture Centeon halted operations at the Kankakee facility in October following a series of plasma product recalls due to suspected bacterial contamination from vial cracks ("The Pink Sheet" Oct. 14, 1996, T&G-7).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth